JNJ — Johnson & Johnson

Is JNJ overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Pharmaceuticals

Overbought As of July 5, 2026

Johnson & Johnson (JNJ) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Pharmaceuticals) last closed at $263.04. The rating moved from Neutral to Overbought on June 24, 2026 and has changed 22 times in the last 90 days.

Public ratingOverbought (as of July 5, 2026)
Last close$263.04
Rating changesRating changed 22 times in the last 90 days
Last changeMoved from Neutral to Overbought on June 24, 2026
SectorHealthcare
IndustryPharmaceuticals

Latest MarketMoodz coverage

Chip Stocks Rally as Goldman’s M&A Streak Spurs Rotation2026-06-29
Salesforce reportedly to buy Fin for $3.6B to beef up Agentforce AI2026-06-15
Goldman Sees Nvidia Upside; What Tech Investors Should Do2026-06-13
Oracle Earnings Loom: Options Price a 12% Move2026-06-09
Eli Lilly Breakout Propels Pharma ETF Rally as J&J Eyes Comeback2026-06-08

See today's live rating, score and targets

Members see the live hourly rating for JNJ — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.